DC
PTCT icon

Diametric Capital’s PTC Therapeutics PTCT Stock Holding History

Diametric Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,596
Closed -$335K – 163
2020
Q2 		$335K Buy
6,596
+125
+2% +$6.14K 0.26% 98
2020
Q1 		$289K Sell
6,471
-29,050
-82% -$1.46M 0.35% 78
2019
Q4 		$1.71M Buy
+35,521
New +$1.51M 1.25% 25
2019
Q3 		– Sell
-44,518
Closed -$2M – 130
2019
Q2 		$2M Buy
+44,518
New +$1.76M 1.27% 27

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Diametric Capital's PTCT Position: Q3 2020 in Review

Diametric Capital sold out of PTC Therapeutics (PTCT) in Q3 2020, closing a stake of 6,596 shares — an estimated $335K sold.

Diametric Capital first reported a position in PTCT in Q2 2019 and held it in 4 quarters. The position peaked at $2M in Q2 2019. 196 funds tracked by Wall St. Rank hold PTCT as of Q3 2020.

  • Diametric Capital reported no remaining PTC Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Diametric Capital sold 6,596 PTC Therapeutics shares in Q3 2020, an estimated $335K.
  • Diametric Capital first reported a position in PTC Therapeutics in Q2 2019 and held it in 4 quarters.
  • Diametric Capital's PTC Therapeutics position peaked at $2M in Q2 2019.
  • 196 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2020.

Based on Diametric Capital's 13F filing for Q3 2020, filed 13 Nov 2020.